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In this issue of the journal, Bangalore and colleagues present an extensive report analysing the relationship between blood pressure values at the time of hospital admission and subsequent clinical outcomes in patients with ischaemic stroke. 1 The findings are reassuring to conventional clinical wisdom: a J-or U-shaped relationship was found between systolic blood pressure and major outcomes overall, and a log-linear relationship was observed between systolic blood pressure and bleeding from fibrinolytic therapy. This is an excellent start to solving the conundrum of targeting a blood pressure value in patients who have just suffered ischaemic stroke, but we can expect major refinement of these findings in the future. The most important progress will occur when we use the same data systems to insert prospective evaluation into the system rather than relying on the 'rear-view mirror' of retrospective analysis. The manuscript of Bangalore and colleagues is the product of a trend that should become a core tenet of medical practice. For conditions and events that occur repeatedly, the best way to understand how to evaluate and treat them is not to rely entirely upon 'expert opinion' or individual experiences seasoned by ad hoc discussions among colleagues. Rather, we should collect accurate information on a large scale and iterate between expert opinion and empirical analyses. Given the choice between a complete guess and expert opinion, I would choose expert opinion, but empirical evidence combined with expert opinion would always be preferable to either.
Until recently, any attempt to extend the use of registries beyond a few selected examples was limited by logistics, the workload imposed by data collection, and the sheer difficulty of dealing with complex data on a massive scale. However, with the support of voluntary groups including the American Heart Association and professional societies, the logistical challenges have been reduced and the increased workload has been justified by the need to demonstrate quality for payment. The fact that data about quality of care are shared by so many hospitals is itself a significant accomplishment. The final challenge-computational and analytical capacity-is no longer a limiting factor, thanks to continuous and rapid improvement in this domain. Accordingly, now is the time to plan for an emerging future in which doctors, healthcare teams, and patients can have confidence that critical healthcare choices are based on the best possible information.
The breadth of this report is itself a notable accomplishment: it comprises baseline data and outcomes on 309 611 patients with ischaemic stroke shared across a national network of hospitals. 1 The analyses are well done and produce gratifying data visualizations, an appealing and useful by-product of modern analytical methods. The consistency of results across hundreds of centres lends confidence that the findings are not idiosyncratic and can be broadly generalized. Yet, impressive as the scope of this work is, we are entering an era in which we can expect more. The study is limited by a lack of detailed information about clinical course, follow-up blood pressure measurements, and interventions that were used. The time factor is critical-extrapolating from an admission value to a therapeutic target is a treacherous undertaking. Continuous measurement of vital signs and integration of this information with changes in patient status could enable much more incisive evaluations of the impact of changes in blood pressure on clinical outcomes. Furthermore, patients with different admission blood pressure values had different underlying risks and it is likely that the pattern of follow-up blood pressure measures will identify additional risk parameters.
2 These issues can be mitigated but not eliminated by statistical approaches-even ones such as the high-quality analysis used in this study.
As we have learned time and time again, there is no substitute for randomization to sort out whether a therapeutic approach is beneficial when compared with alternative approaches. 3 The world of commerce has learned this lesson, as an increasing number of successful businesses routinely use 'A/B comparisons'-in essence, a series of pragmatic randomized trials-to answer common questions about which business practices will optimize outcomes and profit. 4 However, while retailers are deploying sophisticated methods to advertise and sell merchandise, physicians are often obliged to rely on partially educated guesses when treating people with lifethreatening conditions. The fact that the business world is benefitting from approaches that medicine has yet to adopt fully seems both wrong and counterintuitive. However, if we used iterative A/B comparisons more frequently-if randomization is woven into the fabric of healthcare as a whole-clinicians would be more confident that their therapies were based on high-quality empirical evidence, and patients and families could be reassured that they were benefitting from the most appropriate care strategies.
Organizations such as the American Heart Association, the European Society of Cardiology, the American College of Cardiology, and the Society for Thoracic Surgery have driven the development of registries on national and international scales to capture granular information about common procedures and conditions. This growth is being complemented by a massive societal investment in the federation of data from electronic health records (EHRs). The US Food and Drug Administration's Sentinel System 5 has generated claims data from bill- successfully conducting pragmatic trials using existing digital information sources combined with specific data collection unique to each trial to conduct the trials at a fraction of previous costs. If we assume that this fabric of data will continue to improve, the next question is whether we have therapeutic approaches that could 'dial in' a desired blood pressure. Although older drug therapies raise concerns about toxicity or lingering effects, newer therapies are amenable to the minute by minute control that may be desirable during the acute phase of a stroke. 8 In summary, Bangalore and colleagues have given us guidance for the future. Clinicians would in general be wise to 'dial in' a systolic blood pressure of 150 mmHg and to keep systolic blood pressure lower when fibrinolytic therapy is given. However, they would be even wiser to work together to build a system of information that makes such analyses routine by incorporating prospective, randomized 'A/B' comparisons to resolve critical therapeutic questions rapidly. Such a system would improve patients' outcomes and pave the way for developing more effective medications to control blood pressure-therapies that clinicians and patients alike can use with confidence and that doing so will improve outcomes.
